Frequency of Eye Diseases in Subjects Aged 40 and Over. Open Journal of Ophthalmology, 15, 11-17. doi: ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Outside the United States, Lucentis is approved in more than 120 countries to treat adult patients with wet AMD, and for the treatment of visual impairment due to DME, due to macular edema secondary ...

15 patients were female, 17 male. All patients had fluorescein-angiography proven BRVO and at least one injection of Bevacizumab (Avastin ®). Patients were included independently of a prior or ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The continued evolution of treatment protocols and ...

In conclusion, data from high-quality RCTs for ranibizumab and dexamethasone IVT have demonstrated that both new agents have promising outcomes for the treatment of BRVO and CRVO, and constitute ...

Conclusion: The measurements of macular retinal thickness using SD-OCT and SS-OCT devices showed poor consistency and cannot be used interchangeably. However, measurements obtained from different ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.